Jeffrey Cummings, MD, ScD, is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, and Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr. Cummings is globally recognized for his contributions to Alzheimer’s research, drug development, and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Leadership and Achievement Award of the International Society of CNS Drug Development (2018), Bengt Winblad Lifetime Achievement Award of the national Alzheimer’s Association (2019), International Psychogeriatric Association Distinguished Service Award (2019), and Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize. He was featured in Gentleman’s Quarterly (June 2009) as a “Rock Star of Science.” His interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.
Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Mass. U.S. training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Augustas Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association.
Dr. Cummings has authored or edited 43 books and published over 800 peer-reviewed papers.
The biology of Alzheimer’s is complex. This session will cover the latest research at the heart of the amyloid hypothesis, how each new drug in this class is different, and what other innovative solutions are being explored. Key Question: What should all of Us know as we face a disease with very limited treatment options today?
